Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4551 Characterisation and management of neuroendocrine tumours: Findings from a prospective study in Algeria

Introduction: Gastrointestinal neuroendocrine tumours are characterised by varied clinical presentations and behaviours. Their increasing incidence highlights the need for better understanding and management strategies.

Conference:

Presenting Author:

Authors: Zerrouk D, Boukerzaza I, Laouar N, Kassama Z, Mansouri F,

Keywords: Neuroendocrine neoplasm, Observational Study, Treatment Outcomes,

#2206 Metastatic Neuroendocrine Tumor with Unknown Primary Site Presenting Simultaneously with Prostate Adenocarcinoma

Introduction: Neuroendocrine tumors (NET) arise from a variety of different organs and have a steadily increasing incidence in the last 3 decades. 13% of NETs have unknown primary sites.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Enache O, Martin S, Lambrescu I, Sirbu A, Constantin T,

Keywords: neuroendocrine, somatostatin analogs,

#406 YF476, a Gastrin Receptor Antagonist, Causes Regression of Tumors and Normalizes Serum Chromogranin A in Patients with Type 1 Gastric Carcinoids

Introduction: Chronic atrophic gastritis (CAG) results in achlorhydria, hypergastrinemia and, in some patients, gastric carcinoids (type 1 GCs). Type 1 GCs may become malignant and metastasize. Current treatments of type 1 GCs, such as polypectomy, somatostatin analogues and antrectomy, have their disadvantages. YF476 – a potent, selective, orally active and well-tolerated gastrin receptor antagonist in pre-clinical studies – prevented, as well as reduced, the number and size of gastric carcinoids and carcinomas in rodent models.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Fossmark R, Sørdal �, Jianu C, Qvigstad G, Boyce M,

Keywords: gastric carcinoids, gastrin, chromogranin A,